SI3138564T1 - Nalmefen za zmanjšanje uporabe alkohola pri določenih ciljnih populacijah - Google Patents
Nalmefen za zmanjšanje uporabe alkohola pri določenih ciljnih populacijah Download PDFInfo
- Publication number
- SI3138564T1 SI3138564T1 SI201330973T SI201330973T SI3138564T1 SI 3138564 T1 SI3138564 T1 SI 3138564T1 SI 201330973 T SI201330973 T SI 201330973T SI 201330973 T SI201330973 T SI 201330973T SI 3138564 T1 SI3138564 T1 SI 3138564T1
- Authority
- SI
- Slovenia
- Prior art keywords
- nalmefen
- patient
- use according
- alcohol
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Claims (13)
- - ^ ··· ·· NALMEFEN ZA ZMANJŠANJE UPORABE ALKOHOLA PRI DOLOČENIH CILJNIH POPULACIJAH PATENTNI ZAHTEVKI1. Nalmefen za uporabo pri zdravljenju odvisnosti od alkohola pri bolniku z odvisnostjo od alkohola, kjer omenjena uporaba zmanjša porabo alkohola pri omenjenem pacientu; kjer omenjeni pacient z odvisnostjo od alkohola: ima DRL (stopnjo tveganja pitja), kar ustreza porabi >60 g/dan čistega alkohola za moške in >40 g/dan čistega alkohola za ženske; pri čemer omenjeni pacient vzdržuje DRL, ki ustreza porabi >60 g/dan čistega alkohola za moške in >40 g/dan za ženske po opazovanem obdobju po začetni oceni; in kjer je omenjeno opazovalno obdobje po začetnem ocenjevanju 1-2 tedna, kot je približno 2 tedna.
- 2. Nalmefen za uporabo po zahtevku 1, kjer omenjeni pacient ne zahteva takojšne detoksifikacije in/ali pri čemer omenjeni pacient nima fizičnih abstinenčnih simptomov.
- 3. Nalmefen za uporabo po katerem koli od zahtevkov 1-2, kjer je omenjeni pacient podvržen trajni motivacijski podpori.
- 4. Nalmefen za uporabo po katerem koli od zahtevkov 1-3, kjer je omenjeni pacient podvržen svetovanju osredotočenem na povečano privrženost zdravljenju in zmanjšanju porabe alkohola.
- 5. Nalmefen za uporabo po zahtevku 4, kjer omenjeno svetovanje poteka po modelu Brenda.
- 6. Nalmefen za uporabo po katerem koli od zahtevkov 1-5, kjer je navedeni pacient pacient, pri katerem takojšnja abstinenca ni cilj zdravljenja.
- 7. Nalmefen za uporabo po katerem koli od zahtevkov 1-6, kjer se omenjeni nalmefen uporablja za obdobje zdravljenja 6-12 mesecev, kot 6 mesecev.
- 8. Nalmefen za uporabo po katerem koli od zahtevkov 1-7, kjer je omenjeni pacient odrasel ali adolescent.
- 9. Nalmefen za uporabo po katerem koli od zahtevkov 1-8, kjer je omenjeni nalmefen treba uporabiti, kot je potrebno.
- 10. Nalmefen za uporabo po katerem koli od zahtevkov 1-9, pri čemer omenjeni pacient ne spada v eno ali več izmed naslednjih kategorij: pacienti, ki jemljejo opioidne analgetike, pacienti-odvisni od opioidov, brez uspešne abstinence, pacienti z akutnimi simptomi odtegnitve od opioidov, pacienti, za katere se sumi na nedavno uporabo opioidov, pacienti z zmerno ali hudo okvaro jeter, pacienti z zmerno ali hudo okvaro ledvic, pacienti s sedanjo ali nedavno odvisnostjo od opioidov, pacienti z nedavno zgodovino akutnega sindroma odtegnitve alkohola (vključno s halucinacijami, napadi, in delirium tremens). H.Nalmefen za uporabo po katerem koli od zahtevkov 1-10, pri čemer se omenjeni nalmefen uporablja v obliki farmacevtsko sprejemljive kislinske adicijske soli.
- 12. Nalmefen za uporabo po zahtevku 11, kjer se navedeni nalmefen uporablja v obliki hidrokloridne soli.
- 13. Nalmefen za uporabo po zahtevku 12, kjer se navedeni nalmefen uporablja v obliki hidroklorid dihidrata.
- 14. Nalmefen za uporabo po katerem koli od zahtevkov 1-13, kjer se navedeni nalmefen uporablja v obliki peroralne odmerka, kot so tablete ali kapsule.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664804P | 2012-06-27 | 2012-06-27 | |
| US201261721539P | 2012-11-02 | 2012-11-02 | |
| US201261736740P | 2012-12-13 | 2012-12-13 | |
| US201361788810P | 2013-03-15 | 2013-03-15 | |
| EP16187426.8A EP3138564B1 (en) | 2012-06-27 | 2013-06-27 | Nalmefene for reduction of alcohol consumption in specific target populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3138564T1 true SI3138564T1 (sl) | 2018-04-30 |
Family
ID=48703496
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201330449A SI2866808T1 (sl) | 2012-06-27 | 2013-06-27 | Nalmefen za zmanjšanje uporabe alkohola pri določenih ciljnih populacijah |
| SI201332054T SI3345604T1 (sl) | 2012-06-27 | 2013-06-27 | Nalmefen za zmanjšanje pitja alkohola pri specifičnih ciljnih populacijah |
| SI201330973T SI3138564T1 (sl) | 2012-06-27 | 2013-06-27 | Nalmefen za zmanjšanje uporabe alkohola pri določenih ciljnih populacijah |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201330449A SI2866808T1 (sl) | 2012-06-27 | 2013-06-27 | Nalmefen za zmanjšanje uporabe alkohola pri določenih ciljnih populacijah |
| SI201332054T SI3345604T1 (sl) | 2012-06-27 | 2013-06-27 | Nalmefen za zmanjšanje pitja alkohola pri specifičnih ciljnih populacijah |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US20140005217A1 (sl) |
| EP (5) | EP4223296B1 (sl) |
| JP (3) | JP6258933B2 (sl) |
| KR (1) | KR20150023396A (sl) |
| CN (1) | CN104411313A (sl) |
| AU (1) | AU2013283281B2 (sl) |
| BR (1) | BR112014032555A2 (sl) |
| CA (1) | CA2874703C (sl) |
| CL (1) | CL2014003484A1 (sl) |
| CO (1) | CO7160087A2 (sl) |
| CY (3) | CY1118579T1 (sl) |
| DK (3) | DK3345604T3 (sl) |
| EA (1) | EA029908B1 (sl) |
| ES (4) | ES3014068T3 (sl) |
| FI (1) | FI3345604T3 (sl) |
| HK (1) | HK1255683A1 (sl) |
| HR (4) | HRP20161717T1 (sl) |
| HU (4) | HUE070621T2 (sl) |
| IL (1) | IL236035B (sl) |
| LT (3) | LT3138564T (sl) |
| ME (2) | ME03030B (sl) |
| MX (1) | MX371373B (sl) |
| MY (1) | MY166914A (sl) |
| NZ (1) | NZ702191A (sl) |
| PH (1) | PH12014502798A1 (sl) |
| PL (4) | PL3138564T3 (sl) |
| PT (3) | PT2866808T (sl) |
| RS (2) | RS57046B1 (sl) |
| RU (1) | RU2665373C2 (sl) |
| SG (1) | SG11201408704WA (sl) |
| SI (3) | SI2866808T1 (sl) |
| SM (3) | SMT201800164T1 (sl) |
| UA (1) | UA114199C2 (sl) |
| WO (1) | WO2014001427A1 (sl) |
| ZA (1) | ZA201409525B (sl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140005217A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
| WO2014170353A1 (en) * | 2013-04-17 | 2014-10-23 | H. Lundbeck A/S | Nalmefene for treatment of patients with sleep disorder |
| SG11201608766TA (en) | 2014-04-22 | 2016-11-29 | Otsuka Pharma Co Ltd | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
| US20170071590A1 (en) * | 2015-09-10 | 2017-03-16 | Suture Armor Llc | Suture anchor |
| KR102699603B1 (ko) | 2018-04-20 | 2024-08-29 | 삼성전자주식회사 | 반도체 메모리 소자 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3814768A (en) | 1971-11-26 | 1974-06-04 | Lewenstein E | 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts |
| US4535157A (en) | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
| US5086058A (en) * | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
| HUP0401022A3 (en) * | 2001-08-14 | 2006-11-28 | Biotie Therapies Corp | Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse |
| UA102128C2 (en) * | 2008-12-05 | 2013-06-10 | Х. Луннбек А/С | Nalmefene hydrochloride dihydrate |
| EA019331B1 (ru) | 2009-05-25 | 2014-02-28 | Х. Лундбекк А/С | Получение налмефена гидрохлорида из налтрексона |
| RS55777B1 (sr) | 2010-11-05 | 2017-07-31 | H Lundbeck As | Postupak za proizvodnju naltreksona |
| JP5738470B2 (ja) | 2011-03-31 | 2015-06-24 | イムネクス ファーマ イラチュ サナイ ヴェ ティジャレット ア．シェ．Ｉｍｕｎｅｋｓ Ｆａｒｍａ Ｉｌａｃ Ｓａｎａｙｉ Ｖｅ Ｔｉｃａｒｅｔ Ａ．Ｓ． | オピオイド拮抗体組成物、および強皮症の治療のためのその使用 |
| US20140005217A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
-
2013
- 2013-06-26 US US13/928,332 patent/US20140005217A1/en not_active Abandoned
- 2013-06-26 US US13/928,317 patent/US20140005216A1/en not_active Abandoned
- 2013-06-27 LT LTEP16187426.8T patent/LT3138564T/lt unknown
- 2013-06-27 CN CN201380034056.2A patent/CN104411313A/zh active Pending
- 2013-06-27 HR HRP20161717TT patent/HRP20161717T1/hr unknown
- 2013-06-27 PL PL16187426T patent/PL3138564T3/pl unknown
- 2013-06-27 FI FIEP17206034.5T patent/FI3345604T3/fi active
- 2013-06-27 PT PT137324711T patent/PT2866808T/pt unknown
- 2013-06-27 EP EP23163177.1A patent/EP4223296B1/en active Active
- 2013-06-27 PT PT172060345T patent/PT3345604T/pt unknown
- 2013-06-27 DK DK17206034.5T patent/DK3345604T3/da active
- 2013-06-27 HR HRP20230762TT patent/HRP20230762T8/hr unknown
- 2013-06-27 EP EP17206034.5A patent/EP3345604B1/en active Active
- 2013-06-27 DK DK16187426.8T patent/DK3138564T3/en active
- 2013-06-27 HU HUE23163177A patent/HUE070621T2/hu unknown
- 2013-06-27 ME MEP-2018-68A patent/ME03030B/me unknown
- 2013-06-27 ES ES23163177T patent/ES3014068T3/es active Active
- 2013-06-27 DK DK13732471.1T patent/DK2866808T3/en active
- 2013-06-27 LT LTEP13732471.1T patent/LT2866808T/lt unknown
- 2013-06-27 PL PL17206034.5T patent/PL3345604T3/pl unknown
- 2013-06-27 PT PT161874268T patent/PT3138564T/pt unknown
- 2013-06-27 EP EP16187426.8A patent/EP3138564B1/en not_active Revoked
- 2013-06-27 KR KR1020147035322A patent/KR20150023396A/ko not_active Abandoned
- 2013-06-27 SI SI201330449A patent/SI2866808T1/sl unknown
- 2013-06-27 EA EA201492152A patent/EA029908B1/ru not_active IP Right Cessation
- 2013-06-27 SM SM20180164T patent/SMT201800164T1/it unknown
- 2013-06-27 BR BR112014032555A patent/BR112014032555A2/pt not_active Application Discontinuation
- 2013-06-27 JP JP2015519085A patent/JP6258933B2/ja active Active
- 2013-06-27 WO PCT/EP2013/063461 patent/WO2014001427A1/en not_active Ceased
- 2013-06-27 EP EP13732471.1A patent/EP2866808B1/en not_active Revoked
- 2013-06-27 HU HUE13732471A patent/HUE031110T2/en unknown
- 2013-06-27 LT LTEP17206034.5T patent/LT3345604T/lt unknown
- 2013-06-27 MY MYPI2014003570A patent/MY166914A/en unknown
- 2013-06-27 SG SG11201408704WA patent/SG11201408704WA/en unknown
- 2013-06-27 NZ NZ702191A patent/NZ702191A/en not_active IP Right Cessation
- 2013-06-27 PL PL23163177.1T patent/PL4223296T3/pl unknown
- 2013-06-27 RU RU2014151156A patent/RU2665373C2/ru active
- 2013-06-27 SI SI201332054T patent/SI3345604T1/sl unknown
- 2013-06-27 HR HRP20250329TT patent/HRP20250329T1/hr unknown
- 2013-06-27 EP EP24221142.3A patent/EP4541421A3/en active Pending
- 2013-06-27 ES ES16187426.8T patent/ES2663532T3/es active Active
- 2013-06-27 HU HUE16187426A patent/HUE036272T2/hu unknown
- 2013-06-27 MX MX2014015488A patent/MX371373B/es active IP Right Grant
- 2013-06-27 HU HUE17206034A patent/HUE063313T2/hu unknown
- 2013-06-27 CA CA2874703A patent/CA2874703C/en active Active
- 2013-06-27 ES ES13732471.1T patent/ES2609122T3/es active Active
- 2013-06-27 SM SM20160471T patent/SMT201600471T1/it unknown
- 2013-06-27 UA UAA201500199A patent/UA114199C2/uk unknown
- 2013-06-27 ME MEP-2016-286A patent/ME02587B/me unknown
- 2013-06-27 ES ES17206034T patent/ES2950492T3/es active Active
- 2013-06-27 SI SI201330973T patent/SI3138564T1/sl unknown
- 2013-06-27 RS RS20180359A patent/RS57046B1/sr unknown
- 2013-06-27 RS RS20161173A patent/RS55456B1/sr unknown
- 2013-06-27 AU AU2013283281A patent/AU2013283281B2/en not_active Ceased
- 2013-06-27 PL PL13732471T patent/PL2866808T3/pl unknown
-
2014
- 2014-12-02 IL IL236035A patent/IL236035B/en active IP Right Grant
- 2014-12-15 PH PH12014502798A patent/PH12014502798A1/en unknown
- 2014-12-22 CO CO14280546A patent/CO7160087A2/es not_active Application Discontinuation
- 2014-12-22 CL CL2014003484A patent/CL2014003484A1/es unknown
- 2014-12-23 ZA ZA2014/09525A patent/ZA201409525B/en unknown
-
2016
- 2016-04-07 US US15/093,097 patent/US9642849B2/en active Active
- 2016-12-27 SM SM201600471T patent/SMT201600471B/it unknown
-
2017
- 2017-01-03 CY CY20171100004T patent/CY1118579T1/el unknown
- 2017-03-22 US US15/466,024 patent/US10034874B2/en active Active
- 2017-09-22 JP JP2017182608A patent/JP2018039810A/ja not_active Withdrawn
-
2018
- 2018-02-28 HR HRP20180363TT patent/HRP20180363T1/hr unknown
- 2018-03-27 CY CY20181100346T patent/CY1120097T1/el unknown
- 2018-11-20 HK HK18114830.5A patent/HK1255683A1/en unknown
-
2019
- 2019-04-25 JP JP2019083718A patent/JP6857684B2/ja active Active
-
2023
- 2023-07-25 CY CY20231100359T patent/CY1126140T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3138564T1 (sl) | Nalmefen za zmanjšanje uporabe alkohola pri določenih ciljnih populacijah | |
| Suzuki et al. | In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents | |
| CL2014000821A1 (es) | Compuestos derivados de 1h-pirazolo[4,3-c]quinolin-4(5h)-ona, inhibidores de la fosfodiestera 9 (pde9); composicion farmaceutica que los comprende; y agente para mejorar la alteracion cognitiva en la enfermedad de alzheimer. | |
| PA8812601A1 (es) | Forma de dosificacion farmaceutica solida | |
| FI4374878T3 (fi) | Karbetosiinia käsittävä farmaseuttinen koostumus | |
| AR076540A1 (es) | Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor | |
| WO2007088489A3 (en) | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | |
| CL2009002073A1 (es) | Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares. | |
| WO2012031124A3 (en) | Drug formulations using water soluble antioxidants | |
| TNSN08313A1 (fr) | Des formes pharmaceutiques resistantes a la modification | |
| NZ596879A (en) | Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug | |
| CL2007002910A1 (es) | Composicion farmaceutica que comprende compuestos derivados de anillos monociclicos, biciclicos o triciclicos, inhibidores de amidohidrolasa de acidos grasos; complejo que comprende al compuesto; y uso en el tratamiento de enfermedades tales como dol | |
| WO2008144061A3 (en) | Novel combinations comprising a phosphodiesterase-5 inhibitor and their use | |
| BR112015005995A2 (pt) | formulações líquidas de apixaban | |
| Matsuura et al. | Fluorescent visualisation of oxytocin in the hypothalamo‐neurohypophysial/‐spinal pathways after chronic inflammation in oxytocin‐monomeric red fluorescent protein 1 transgenic rats | |
| BR112014009438A2 (pt) | composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral | |
| CO6341547A2 (es) | Uso de antagonistas opioides para el tratamiento de retencion urinaria | |
| WO2008030830A3 (en) | Sustained-release composition and method of use thereof | |
| EA201171271A1 (ru) | Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида | |
| MX2009003771A (es) | Formulaciones robustas de liberacion sostenida. | |
| WO2012075023A3 (en) | Neoantibodies for diagnosing tissue injury | |
| BRPI0518426A2 (pt) | composiÇÕes farmacÊuticas compreendendo fenofibratos e sistemas solventes | |
| EP2508192A4 (en) | MEANS FOR THE TREATMENT AND PREVENTION OF DISEASES OF MALE UROGENITAL STRATEGY | |
| CO6331424A2 (es) | Formulacion farmaceutica de eprosartan | |
| Ahn et al. | The effect of social relationship on unmarried mother's self-esteem |